Uceris Available For UC Patients In March



February 8, 2013

 

On Jan 14th the Food & Drug Administration approved the drug UCERIS (Budesonide) for the induction of remission in patients with mild to moderate ulcerative colitis.   Uceris can be used for patients who are not responding to other medications prescribed for Inflammatory Bowel Diseases.

"In patients that are not responding to 5-ASAs or cannot use 5-ASAs with mild to moderate disease activity, Uceris may be used as an alternative to prednisone for inducing remission," says Dr. Faten N. Aberra. "Uceris is only indicated for inducing remission for up to 8 weeks and not a maintenance medication."

The medication will be available to the public in March 2013.  For more details on this new medication check out the Santarus website: http://ir.santarus.com/releasedetail.cfm?ReleaseID=733438.


Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 80 cents of every dollar the Foundation spends going to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org).

733 Third Avenue, Suite 510, New York, NY 10017    |    800-932-2423    |    info@crohnscolitisfoundation.org
Powered by Blackbaud
nonprofit software